Lexaria Bioscience Corp. LEXX 深 沪
等待开盘 02-02 09:30:00 美东时间
0.7837
+0.028
+3.68%
华盛通- 最 高0.80
- 今 开0.766
- 成交量 16.30万股
- 最 低 0.7202
- 昨 收 0.7559
- 总市值 1950.43万
- 52周最高 1.8955
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 0.46
- 委 比 -87.28%
- 总股本 2488.74万
- 历史最高 12.50
- 量 比 1.30
- 振 幅 10.56%
- 历史最低 0.46
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
2025-12-26 19:06
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.
2025-12-24 01:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
2025-12-17 05:05
UPDATE: Lexaria Bioscience Announces $3.5M Registered Direct Offering Of 2,661,600 Shares At A Price Of $1.315/Share
Lexaria Bioscience Corp. (NASDAQ:LEXX)(LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an
2025-12-15 21:51
Lexaria Extends Partnership With PharmaCO To April 2026 For Ongoing Evaluation Of DehydraTECH, Following Australian Study Data Review
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on
2025-11-12 22:12
Lexaria Bioscience Expands Strategic Outreach and Secures New Patents
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience Corp. h...
2025-10-09 23:08
Lexaria Awarded 4 New Patents Covering Therapeutics For Diabetes, Hypertension, Seizure Disorders, And Antiviral Treatments
Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intellectual property portfolio. These patents support the immense value of our strategic R&D
2025-10-09 21:23
